Previous 10 | Next 10 |
Treatment with Nomacopan (Coversin) in three patients with mild-to-moderate bullous pemphigoid (BP) resulted in no drug-related adverse events and rapid reduction in BP Disease Area Index (BPDAI) score and blistering in ongoing Phase II clinical trial Pivotal clinical trial for pediat...
CORAL GABLES, FL / ACCESSWIRE / April 23, 2019 / The stock market is on the verge of setting new record highs today April 23, 2019. Previous highs for the SPY from 2018 was $293.94 and today Tuesday 4/23/2019 the SPY has already hit highs of $293.14. Positive sentiment surrounding global tr...
Gainers: Atossa Genetics (NASDAQ: ATOS ) +28% . Immunic (NASDAQ: IMUX ) +22% . Akari Therapeutics (NASDAQ: AKTX ) +19% . Superconductor Technologies (NASDAQ: SCON ) +18% . X4 Pharmaceuticals (NASDAQ: XFOR ) +17% . Hasbro (NASDAQ: HAS ) +16% . Twitter (NYSE: TWTR ) +16% . Trova...
TrovaGene (NASDAQ: TROV ) +22% on positive onvansertib data . More news on: TrovaGene, Inc., Akari Therapeutics, Plc, Hasbro, Inc., Stocks on the move, Read more ...
Nano cap Akari Therapeutics (NASDAQ: AKTX ) is up 25% premarket on increased volume in reaction to positive data from a Phase 2 clinical trial evaluating second-generation complement inhibitor Coversin (nomacopan) in patients with a rare inflammatory skin condition called bull...
NEW YORK and LONDON, April 23, 2019 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement and/or leukotriene systems are implicated, announces posit...
Poster to be presented on back-of-the-eye program including data from uveitis preclinical model Interim data expected from Akari’s Phase I/II clinical trial in atopic keratoconjunctivitis (AKC), a surface of the eye inflammatory disease NEW YORK and LONDON, March 27, 2019 ...
Akari Therapeutics (NASDAQ: AKTX ) has filed a prospectus for the sale by holder Aspire Capital Fund of 500M ordinary shares . More news on: Akari Therapeutics, Plc, Healthcare stocks news, Stocks on the move, Read more ...
Altimmune (NASDAQ: ALT ) +44% on positive NasoVAX data . More news on: Altimmune, Inc., Vaxart, Inc., Cellectar Biosciences, Inc., Stocks on the move, Read more ...
CORAL GABLES, FL / ACCESSWIRE / March 18, 2019 / The tech stock market is truly miraculous, mainly because the tech industry never ceases to amaze consumers as companies consistently demonstrate their ability to innovate towards the future. Over the course of the last few months, we've see...
News, Short Squeeze, Breakout and More Instantly...
Akari Therapeutics Plc Company Name:
AKTX Stock Symbol:
NASDAQ Market:
PRA Group Inc. (PRAA) is expected to report $-0.15 for Q1 2024 Bowman Consulting Group Ltd. (BWMN) is expected to report $-0.04 for Q1 2024 Noble Corporation plc A (NE) is expected to report $0.56 for Q1 2024 Velo3D Inc. (VLD) is expected to report for Q3 2024 Axon Enterprise Inc....
BOSTON and LONDON, May 01, 2024 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), a biotechnology company developing advanced therapies...
Prioritization of Peak's ADC cancer therapeutic platform technology and Akari's PAS-nomacopan for Geographic Atrophy, a disabling ophth...